GW hosted a conference call with pharmaceuticals analysts today.... more
GW is today providing an update on the progress of its regulatory filings for Sativex in the UK and Canada.... more
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial to assess the effects of Sativex® on spasticity in 189 patients with Multiple Sclerosis (MS).... more
GW Pharmaceuticals plc, the company which is developing a range of new medicines based on cannabis and other controlled drugs, announces its interim results for the six months ended 31 March 2004.... more
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial with Sativex® in 125 patients with neuropathic (nerve damage) pain.... more
GW Pharmaceuticals plc announces positive preliminary results in a Phase II clinical trial in patients with pain caused by Rheumatoid Arthritis.... more
GW Pharmaceuticals plc (“GW” or “the Company”) and Bayer HealthCare, Pharmaceuticals Division - Canada (“Bayer”) announce that GW has submitted a New Drug Submission for Sativex®, a cannabis-based med... more
On 21 January 2004, GW announced that it expected the regulatory assessment process for Sativex to be completed during the second quarter of 2004.... more
GW Pharmaceuticals is pleased to announce that, at the Annual General Meeting of the Company held earlier today, all of the resolutions proposed were duly passed. ... more
GW Pharmaceuticals plc, the company which develops a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 September 2003.... more
GW announces that it has appointed N M Rothschild & Sons as its financial adviser and Hoare Govett Limited as its Nominated Adviser and broker with immediate effect.... more
